Sequencing BCMA-Directed Therapies Expands Multiple Myeloma Treatment Horizons

Sikander Ailawadhi, MD, spotlights the characteristics of multiple myeloma that drive the decision to use teclistamab-cqyv, elranatamab-bcmm, or talquetamab-tgvs.

Related Keywords

United States ,Florida ,Jacksonville ,American ,Sikander Ailawadhi ,National Cancer Institute ,Mayo Clinic ,Institutional Perspectives ,African American ,Teclistamab ,Elranatamab ,Talquetamab ,Onclive Institutional Perspectives In Cancer ,D ,Myeloma ,Multiple Myeloma ,